Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Encompass Health CorpEHC · Entity 3460 | Director | July 15, 2026 | July 16, 2026 |
| IONIS PHARMACEUTICALS INCIONS · Entity 1182 | Director | July 15, 2026 | July 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Encompass Health Corp
Report date July 15, 2026 · Filed July 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Encompass Health Common StockSEC Table I · non-derivative | Direct | 49,643 |
Reported balance
After 2026-07-15 transaction · row 1
1 source rowRow 1 · 2026-07-15 · Grant · Acquired 85 · Balance 49,643 F1: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 15, 2026, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $109.88. The transaction reported on this Form 4 is an award of RSUs as sociated with that dividend payment. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 15, 2026, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $109.88. The transaction reported on this Form 4 is an award of RSUs as sociated with that dividend payment.
IONIS PHARMACEUTICALS INC
Report date July 15, 2026 · Filed July 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 51,306 |
Reported balance
After 2026-07-15 transaction · row 1
1 source rowRow 1 · 2026-07-15 · Exercise / conversion · Acquired 5,220 · Balance 51,306 F1: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 2,301 |
Reported balance
After 2026-07-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-15 · Exercise / conversion · Disposed 5,220 · Balance 2,301 F2: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F3: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.
F2: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.
F3: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CONVERGYS CORP
Report date October 05, 2018 · Filed October 10, 2018
Section 16 reporting ended · disclosed 2018-10-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2018-10-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-10-05 · Disposition to issuer · Disposed 11,923 · Balance 33,612 F1: At the Effective Time (as defined in the Agreement and Plan of Merger, dated June 28, 2018 (as amended, the "Merger Agreement"), by and among the Company, SYNNEX Corporation, Delta Merger Sub I, Inc. and Concentrix CVG Corporation), these time-based restricted stock units and deferred stock units were converted into the right to receive $295,213.48 in cash, which amount will vest and be paid in accordance with the Merger Agreement and the applicable award agreements. Row 2 · 2018-10-05 · Disposition to issuer · Disposed 33,612 · Balance 0 F2: At the Effective Time, these shares were cancelled pursuant to the Merger Agreement in exchange for the right to receive $445,359 in cash and 4,245.20 shares of SYNNEX Corporation common stock having a market value of $89.14 per share, based on the closing price of SYNNEX common stock on October 5, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: At the Effective Time (as defined in the Agreement and Plan of Merger, dated June 28, 2018 (as amended, the "Merger Agreement"), by and among the Company, SYNNEX Corporation, Delta Merger Sub I, Inc. and Concentrix CVG Corporation), these time-based restricted stock units and deferred stock units were converted into the right to receive $295,213.48 in cash, which amount will vest and be paid in accordance with the Merger Agreement and the applicable award agreements.
F2: At the Effective Time, these shares were cancelled pursuant to the Merger Agreement in exchange for the right to receive $445,359 in cash and 4,245.20 shares of SYNNEX Corporation common stock having a market value of $89.14 per share, based on the closing price of SYNNEX common stock on October 5, 2018.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 15, 2026 Filed Jul 16, 2026 20:12 UTC | Encompass Health Corp EHC · Entity 3460 | GrantEncompass Health Common Stock | 85 | $0.00 | $0.00 |
DisclosureSEC source: 0000785161-26-000168 · form4.xml · nonDerivative · entry 1 HERMAN JOAN E · CIK 0001248398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,643 F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 15, 2026, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $109.88. The transaction reported on this Form 4 is an award of RSUs as sociated with that dividend payment. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 21:12 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Unit · Derivative | 5,220 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-26-000245 · edgardoc.xml · derivative · entry 2 HERMAN JOAN E · CIK 0001248398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,301 Underlying: Common Stock · 5,220 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F3 · derivative.exercise_date: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company. F3 · derivative.expiration_date: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 21:12 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 5,220 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-26-000245 · edgardoc.xml · nonDerivative · entry 1 HERMAN JOAN E · CIK 0001248398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,306 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 22:49 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantRestricted Stock Unit · Derivative | 2,301 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-26-000230 · edgardoc.xml · derivative · entry 2 HERMAN JOAN E · CIK 0001248398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,521 Underlying: Common Stock · 2,301 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2026 totals no more than $400,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718. F4 · derivative.exercise_date: Grant on July 1, 2026 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2026. F4 · derivative.expiration_date: Grant on July 1, 2026 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2026. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 22:49 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 5,369 | $0.00 Strike: $79.19 | $0.00 |
DisclosureSEC source: 0000874015-26-000230 · edgardoc.xml · derivative · entry 1 HERMAN JOAN E · CIK 0001248398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,369 Underlying: Common Stock · 5,369 shares Expires 2036-06-30 F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2026 totals no more than $400,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718. F2 · derivative.exercise_date: Grant on July 1, 2026 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2026. F2 · derivative.expiration_date: Grant on July 1, 2026 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2026. Read SEC document |
| May 07, 2026 Filed May 11, 2026 15:32 UTC | Encompass Health Corp EHC · Entity 3460 | GrantEncompass Health Common Stock | 1,634 | $0.00 | $0.00 |
DisclosureSEC source: 0000785161-26-000134 · form4.xml · nonDerivative · entry 1 HERMAN JOAN E · CIK 0001248398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,558 F1 · shares: Annual grant of restricted stock units pursuant to the Corporation's 2025 Omnibus Performance Incentive Plan. Read SEC document |
| April 15, 2026 Filed Apr 16, 2026 18:46 UTC | Encompass Health Corp EHC · Entity 3460 | GrantEncompass Health Common Stock | 85 | $0.00 | $0.00 |
DisclosureSEC source: 0000785161-26-000119 · form4.xml · nonDerivative · entry 1 HERMAN JOAN E · CIK 0001248398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,924 F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 15, 2026, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $105.24. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment. Read SEC document |
| January 15, 2026 Filed Jan 16, 2026 21:25 UTC | Encompass Health Corp EHC · Entity 3460 | GrantEncompass Health Common Stock | 87 | $0.00 | $0.00 |
DisclosureSEC source: 0000785161-26-000014 · form4.xml · nonDerivative · entry 1 HERMAN JOAN E · CIK 0001248398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,839 F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On January 15, 2026, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $102.80. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment. Read SEC document |
| November 19, 2025 Filed Nov 20, 2025 22:12 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 32,000 | $0.00 Strike: $63.90 | $0.00 |
DisclosureSEC source: 0000874015-25-000281 · edgardoc.xml · derivative · entry 6 HERMAN JOAN E · CIK 0001248398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,000 shares Expires 2029-06-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 19, 2025 Filed Nov 20, 2025 22:12 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $40.05 | $0.00 |
DisclosureSEC source: 0000874015-25-000281 · edgardoc.xml · derivative · entry 5 HERMAN JOAN E · CIK 0001248398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2031-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 19, 2025 Filed Nov 20, 2025 22:12 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 32,000 | $72.13 | $2,308,240.00 |
DisclosureSEC source: 0000874015-25-000281 · edgardoc.xml · nonDerivative · entry 4 HERMAN JOAN E · CIK 0001248398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,086 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.985 to $72.33 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) on this Form 4. Read SEC document |
| November 19, 2025 Filed Nov 20, 2025 22:12 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 32,000 | $63.90 | $2,044,800.00 |
DisclosureSEC source: 0000874015-25-000281 · edgardoc.xml · nonDerivative · entry 3 HERMAN JOAN E · CIK 0001248398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,086 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 19, 2025 Filed Nov 20, 2025 22:12 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 12,000 | $72.13 | $865,590.00 |
DisclosureSEC source: 0000874015-25-000281 · edgardoc.xml · nonDerivative · entry 2 HERMAN JOAN E · CIK 0001248398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,086 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.985 to $72.33 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) on this Form 4. Read SEC document |
| November 19, 2025 Filed Nov 20, 2025 22:12 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 12,000 | $40.05 | $480,600.00 |
DisclosureSEC source: 0000874015-25-000281 · edgardoc.xml · nonDerivative · entry 1 HERMAN JOAN E · CIK 0001248398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,086 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 15, 2025 Filed Oct 16, 2025 19:42 UTC | Encompass Health Corp EHC · Entity 3460 | GrantEncompass Health Common Stock | 73 | $0.00 | $0.00 |
DisclosureSEC source: 0000785161-25-000106 · form4.xml · nonDerivative · entry 1 HERMAN JOAN E · CIK 0001248398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,752 F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 15, 2025, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $123.65. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment. Read SEC document |
| July 15, 2025 Filed Jul 16, 2025 18:10 UTC | Encompass Health Corp EHC · Entity 3460 | GrantEncompass Health Common Stock | 74 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-019247 · form4.xml · nonDerivative · entry 1 HERMAN JOAN E · CIK 0001248398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,679 F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 15, 2025, Encompass Health paid a dividend on its common stock of $0.17 per share and the closing price was $107.28. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment. Read SEC document |
| July 15, 2025 Filed Jul 17, 2025 20:54 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Unit · Derivative | 4,079 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-25-000158 · edgardoc.xml · derivative · entry 2 HERMAN JOAN E · CIK 0001248398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,220 Underlying: Common Stock · 4,079 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F3 · derivative.exercise_date: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company. F3 · derivative.expiration_date: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| July 15, 2025 Filed Jul 17, 2025 20:54 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 4,079 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-25-000158 · edgardoc.xml · nonDerivative · entry 1 HERMAN JOAN E · CIK 0001248398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,086 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 20:53 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantRestricted Stock Unit · Derivative | 5,220 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-25-000139 · edgardoc.xml · derivative · entry 2 HERMAN JOAN E · CIK 0001248398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,299 Underlying: Common Stock · 5,220 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2025 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718. F4 · derivative.exercise_date: Grant on July 1, 2025 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2025. F4 · derivative.expiration_date: Grant on July 1, 2025 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2025. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 20:53 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 11,518 | $0.00 Strike: $39.94 | $0.00 |
DisclosureSEC source: 0000874015-25-000139 · edgardoc.xml · derivative · entry 1 HERMAN JOAN E · CIK 0001248398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,518 Underlying: Common Stock · 11,518 shares Expires 2035-06-30 F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2025 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718. F2 · derivative.exercise_date: Grant on July 1, 2025 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2025. F2 · derivative.expiration_date: Grant on July 1, 2025 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2025. Read SEC document |
| May 01, 2025 Filed May 2, 2025 18:34 UTC | Encompass Health Corp EHC · Entity 3460 | GrantEncompass Health Common Stock | 1,424 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-013136 · form4.xml · nonDerivative · entry 1 HERMAN JOAN E · CIK 0001248398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,605 F1 · shares: Annual grant of restricted stock units pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan. Read SEC document |
| April 15, 2025 Filed Apr 16, 2025 20:58 UTC | Encompass Health Corp EHC · Entity 3460 | GrantEncompass Health Common Stock | 76 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-012158 · form4.xml · nonDerivative · entry 1 HERMAN JOAN E · CIK 0001248398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,181 F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 15, 2025, Encompass Health paid a dividend on its common stock of $0.17 per share and the closing price was $102.30. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 19:47 UTC | Encompass Health Corp EHC · Entity 3460 | GrantEncompass Health Common Stock | 83 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-001402 · form4.xml · nonDerivative · entry 1 HERMAN JOAN E · CIK 0001248398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,105 F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On January 15, 2025, Encompass Health paid a dividend on its common stock of $0.17 per share and the closing price was $93.61. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment. Read SEC document |
| October 15, 2024 Filed Oct 17, 2024 17:07 UTC | Encompass Health Corp EHC · Entity 3460 | GrantEncompass Health Common Stock | 81 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-025657 · form4.xml · nonDerivative · entry 1 HERMAN JOAN E · CIK 0001248398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,022 F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 15, 2024, Encompass Health paid a dividend on its common stock of $0.17 per share and the closing price was $96.33. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 20:05 UTC | Encompass Health Corp EHC · Entity 3460 | GrantEncompass Health Common Stock | 80 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-020552 · form4.xml · nonDerivative · entry 1 HERMAN JOAN E · CIK 0001248398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,941 F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 15, 2024, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $85.49. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 21:02 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Unit · Derivative | 4,677 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-24-000179 · edgardoc.xml · derivative · entry 2 HERMAN JOAN E · CIK 0001248398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,079 Underlying: Common Stock · 4,677 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F3 · derivative.exercise_date: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company. F3 · derivative.expiration_date: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 21:02 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 4,677 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-24-000179 · edgardoc.xml · nonDerivative · entry 1 HERMAN JOAN E · CIK 0001248398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,007 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 18:47 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantRestricted Stock Unit · Derivative | 4,079 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-24-000162 · edgardoc.xml · derivative · entry 2 HERMAN JOAN E · CIK 0001248398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,756 Underlying: Common Stock · 4,079 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2024 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718. F4 · derivative.exercise_date: Grant on July 1, 2024 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2024. F4 · derivative.expiration_date: Grant on July 1, 2024 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2024. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 18:47 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 10,111 | $0.00 Strike: $47.11 | $0.00 |
DisclosureSEC source: 0000874015-24-000162 · edgardoc.xml · derivative · entry 1 HERMAN JOAN E · CIK 0001248398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,111 Underlying: Common Stock · 10,111 shares Expires 2034-06-30 F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2024 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718. F2 · derivative.exercise_date: Grant on July 1, 2024 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2024. F2 · derivative.expiration_date: Grant on July 1, 2024 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2024. Read SEC document |
| May 02, 2024 Filed May 3, 2024 17:09 UTC | Encompass Health Corp EHC · Entity 3460 | GrantEncompass Health Common Stock | 1,978 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-014070 · form4.xml · nonDerivative · entry 1 HERMAN JOAN E · CIK 0001248398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,861 F1 · shares: Annual grant of restricted stock units pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan. Read SEC document |
| April 15, 2024 Filed Apr 16, 2024 20:45 UTC | Encompass Health Corp EHC · Entity 3460 | GrantEncompass Health Common Stock | 80 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-013008 · form4.xml · nonDerivative · entry 1 HERMAN JOAN E · CIK 0001248398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,883 F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 15, 2024, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $80.73. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment Read SEC document |
| January 16, 2024 Filed Jan 17, 2024 21:10 UTC | Encompass Health Corp EHC · Entity 3460 | GrantEncompass Health Common Stock | 91 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-001413 · form4.xml · nonDerivative · entry 1 HERMAN JOAN E · CIK 0001248398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,803 F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On January 16, 2024, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $71.45. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment. Read SEC document |
| October 16, 2023 Filed Oct 17, 2023 21:17 UTC | Encompass Health Corp EHC · Entity 3460 | GrantEncompass Health Common Stock | 101 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-026013 · form4.xml · nonDerivative · entry 1 HERMAN JOAN E · CIK 0001248398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,712 F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 16, 2023, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $63.77. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment. Read SEC document |
| July 17, 2023 Filed Jul 18, 2023 17:51 UTC | Encompass Health Corp EHC · Entity 3460 | GrantEncompass Health Common Stock | 95 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-020905 · form4.xml · nonDerivative · entry 1 HERMAN JOAN E · CIK 0001248398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,611 F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 17, 2023, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $67.54. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment. Read SEC document |
| July 17, 2023 Filed Jul 19, 2023 22:05 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Unit · Derivative | 5,333 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-23-000175 · edgardoc.xml · derivative · entry 4 HERMAN JOAN E · CIK 0001248398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,677 Underlying: Common Stock · 5,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F4 · derivative.exercise_date: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company. F4 · derivative.expiration_date: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| July 17, 2023 Filed Jul 19, 2023 22:05 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Unit · Derivative | 1,777 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-23-000175 · edgardoc.xml · derivative · entry 3 HERMAN JOAN E · CIK 0001248398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,010 Underlying: Common Stock · 1,777 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F3 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F3 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| July 17, 2023 Filed Jul 19, 2023 22:05 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 5,333 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-23-000175 · edgardoc.xml · nonDerivative · entry 2 HERMAN JOAN E · CIK 0001248398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,330 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. Read SEC document |
| July 17, 2023 Filed Jul 19, 2023 22:05 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 1,777 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-23-000175 · edgardoc.xml · nonDerivative · entry 1 HERMAN JOAN E · CIK 0001248398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,997 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. Read SEC document |
| July 03, 2023 Filed Jul 6, 2023 21:14 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantRestricted Stock Unit · Derivative | 4,677 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-23-000157 · edgardoc.xml · derivative · entry 2 HERMAN JOAN E · CIK 0001248398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,787 Underlying: Common Stock · 4,677 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2023 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718. F4 · derivative.exercise_date: Grant on July 3, 2023 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 3, 2023. F4 · derivative.expiration_date: Grant on July 3, 2023 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 3, 2023. Read SEC document |
| July 03, 2023 Filed Jul 6, 2023 21:14 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 10,321 | $0.00 Strike: $41.08 | $0.00 |
DisclosureSEC source: 0000874015-23-000157 · edgardoc.xml · derivative · entry 1 HERMAN JOAN E · CIK 0001248398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,321 Underlying: Common Stock · 10,321 shares Expires 2033-07-02 F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2023 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718. F2 · derivative.exercise_date: Grant on July 3, 2023 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 3, 2023. F2 · derivative.expiration_date: Grant on July 3, 2023 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 3, 2023. Read SEC document |
| June 12, 2023 Filed Jun 14, 2023 20:50 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Unit · Derivative | 3,555 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-23-000142 · edgardoc.xml · derivative · entry 2 HERMAN JOAN E · CIK 0001248398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,110 Underlying: Common Stock · 3,555 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F3 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F3 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| June 12, 2023 Filed Jun 14, 2023 20:50 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 3,555 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-23-000142 · edgardoc.xml · nonDerivative · entry 1 HERMAN JOAN E · CIK 0001248398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,220 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. Read SEC document |
| May 04, 2023 Filed May 8, 2023 17:08 UTC | Encompass Health Corp EHC · Entity 3460 | GrantEncompass Health Common Stock | 2,385 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-014819 · form4.xml · nonDerivative · entry 1 HERMAN JOAN E · CIK 0001248398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,516 F1 · shares: Annual grant of restricted stock units pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan. Read SEC document |
| April 17, 2023 Filed Apr 19, 2023 17:19 UTC | Encompass Health Corp EHC · Entity 3460 | GrantEncompass Health Common Stock | 99 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-013208 · form4.xml · nonDerivative · entry 1 HERMAN JOAN E · CIK 0001248398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,131 F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 17, 2023, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $61.39. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 16:39 UTC | Encompass Health Corp EHC · Entity 3460 | GrantEncompass Health Common Stock | 99 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-001739 · form4.xml · nonDerivative · entry 1 HERMAN JOAN E · CIK 0001248398 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,032 F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On January 17, 2023, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $61.16. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment. Read SEC document |
| October 17, 2022 Filed Oct 19, 2022 15:04 UTC | Encompass Health Corp EHC · Entity 3460 | GrantEncompass Health Common Stock | 123 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-024114 · form4.xml · nonDerivative · entry 1 HERMAN JOAN E · CIK 0001248398 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,933 F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 17, 2022, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $48.81. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment. Read SEC document |
| July 20, 2022 Filed Jul 21, 2022 20:58 UTC | Encompass Health Corp EHC · Entity 3460 | GrantEncompass Health Common Stock | 226 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-019595 · form4.xml · nonDerivative · entry 1 HERMAN JOAN E · CIK 0001248398 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,093 F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 20, 2022, Encompass Health paid a dividend on its common stock of $0.28 per share and the closing price was $49.19. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment. Read SEC document |
| July 15, 2022 Filed Jul 19, 2022 23:20 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Unit · Derivative | 1,777 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-22-000139 · edgardoc.xml · derivative · entry 4 HERMAN JOAN E · CIK 0001248398 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,665 Underlying: Common Stock · 1,777 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F4 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company. F4 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| July 15, 2022 Filed Jul 19, 2022 23:20 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Unit · Derivative | 5,333 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-22-000139 · edgardoc.xml · derivative · entry 3 HERMAN JOAN E · CIK 0001248398 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,442 Underlying: Common Stock · 5,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F3 · derivative.exercise_date: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company. F3 · derivative.expiration_date: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| July 15, 2022 Filed Jul 19, 2022 23:20 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 1,777 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-22-000139 · edgardoc.xml · nonDerivative · entry 2 HERMAN JOAN E · CIK 0001248398 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,665 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.